{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T02:58:07Z","timestamp":1794452287596,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pulmonary embolism (PE) and its sequelae impact healthcare systems globally. Low-risk PE patients can be managed with early discharge strategies leading to cost savings, but post-discharge costs are undetermined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To define healthcare resource utilisation and overall costs during follow-up of low-risk PE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We used an incidence-based, bottom\u2013up approach and calculated direct and indirect costs over 3-month follow-up after low-risk PE, with data from the Home Treatment of Patients with Low-Risk Pulmonary Embolism (HoT-PE) cohort study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Average 3-month costs per patient having suffered low-risk PE were 7029.62 \u20ac; of this amount, 4872.93 \u20ac were associated with PE, accounting to 69.3% of total costs. Specifically, direct costs totalled 3019.33 \u20ac, and of those, 862.64 \u20ac (28.6%) were associated with PE. Anticoagulation (279.00 \u20ac), rehospitalisations (296.83 \u20ac), and ambulatory visits (194.95 \u20ac) comprised the majority of the 3-month direct costs. The remaining costs amounting to 4010.29 \u20ac were indirect costs due to loss of productivity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In a patient cohort with acute low-risk PE followed over 3\u00a0months, the majority of costs were indirect costs related to productivity loss, whereas direct, PE-specific post-discharge costs were low. Effective interventions are needed to reduce the burden of PE and associated costs, especially those related to productivity loss.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00392-023-02355-5","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:02:43Z","timestamp":1704290563000},"page":"168-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Healthcare resource utilisation and associated costs after low-risk pulmonary embolism: pre-specified analysis of the Home Treatment of Pulmonary Embolism (HoT-PE) study"],"prefix":"10.1007","volume":"114","author":[{"given":"Ioannis T.","family":"Farmakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Hobohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Barco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6359-7279","authenticated-orcid":false,"given":"Stavros V.","family":"Konstantinides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"issue":"11","key":"2355_CR1","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","volume":"34","author":"GE Raskob","year":"2014","unstructured":"Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ et al (2014) Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 34(11):2363\u20132371","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"2355_CR2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1160\/TH15-08-0670","volume":"115","author":"S Barco","year":"2016","unstructured":"Barco S, Woersching AL, Spyropoulos AC, Piovella F, Mahan CE (2016) European Union-28: an annualised cost-of-illness model for venous thromboembolism. Thromb Haemost 115(4):800\u2013808","journal-title":"Thromb Haemost"},{"issue":"4","key":"2355_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41(4):543\u2013603","journal-title":"Eur Heart J"},{"issue":"6","key":"2355_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1055\/s-0040-1722189","volume":"121","author":"AM Wendelboe","year":"2021","unstructured":"Wendelboe AM, Campbell J, Ding K, Bratzler DW, Beckman MG, Reyes NL et al (2021) Incidence of venous thromboembolism in a racially diverse population of Oklahoma County, Oklahoma. Thromb Haemost 121(6):816\u2013825","journal-title":"Thromb Haemost"},{"issue":"3","key":"2355_CR5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2213-2600(19)30354-6","volume":"8","author":"S Barco","year":"2020","unstructured":"Barco S, Mahmoudpour SH, Valerio L, Klok FA, Munzel T, Middeldorp S et al (2020) Trends in mortality related to pulmonary embolism in the European Region, 2000\u201315: analysis of vital registration data from the WHO mortality database. Lancet Respir Med 8(3):277\u2013287","journal-title":"Lancet Respir Med"},{"key":"2355_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1024\/0301-1526\/a001042","volume":"52","author":"IT Farmakis","year":"2022","unstructured":"Farmakis IT, Keller K, Barco S, Konstantinides SV, Hobohm L (2022) From acute pulmonary embolism to post-pulmonary embolism sequelae. Vasa 52:29\u201337","journal-title":"Vasa"},{"key":"2355_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.1901","author":"L Valerio","year":"2022","unstructured":"Valerio L, Mavromanoli AC, Barco S, Abele C, Becker D, Bruch L et al (2022) Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehac544.1901","journal-title":"Eur Heart J"},{"key":"2355_CR8","doi-asserted-by":"publisher","first-page":"e027514","DOI":"10.1161\/JAHA.122.027514","volume":"14","author":"IT Farmakis","year":"2022","unstructured":"Farmakis IT, Barco S, Mavromanoli AC, Agnelli G, Cohen AT, Giannakoulas G et al (2022) Cost-of-illness analysis of long-term health care resource use and disease burden in patients with pulmonary embolism: insights from the PREFER in VTE registry. J Am Heart Assoc 14:e027514","journal-title":"J Am Heart Assoc"},{"key":"2355_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1055\/a-2031-3859","volume":"123","author":"C Becattini","year":"2023","unstructured":"Becattini C, Agnelli G, Maggioni AP, Dentali F, Fabbri A, Enea I et al (2023) Contemporary management and clinical course of acute pulmonary embolism: the COPE study. Thromb Haemost 123:613\u2013626","journal-title":"Thromb Haemost"},{"issue":"4","key":"2355_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/eurheartj\/ehz367","volume":"41","author":"S Barco","year":"2020","unstructured":"Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E et al (2020) Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J 41(4):509\u2013518","journal-title":"Eur Heart J"},{"issue":"33","key":"2355_CR11","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1093\/eurheartj\/ehab373","volume":"42","author":"P-M Roy","year":"2021","unstructured":"Roy P-M, Penaloza A, Hugli O, Klok FA, Arnoux A, Elias A et al (2021) Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial. Eur Heart J 42(33):3146\u20133157","journal-title":"Eur Heart J"},{"issue":"2","key":"2355_CR12","doi-asserted-by":"publisher","first-page":"2002368","DOI":"10.1183\/13993003.02368-2020","volume":"57","author":"S Barco","year":"2021","unstructured":"Barco S, Schmidtmann I, Ageno W, Anusic T, Bauersachs RM, Becattini C et al (2021) Survival and quality of life after early discharge in low-risk pulmonary embolism. Eur Respir J 57(2):2002368","journal-title":"Eur Respir J"},{"issue":"07","key":"2355_CR13","first-page":"191","volume":"116","author":"S Barco","year":"2017","unstructured":"Barco S, Lankeit M, Binder H, Schellong S, Christ M, Beyer-Westendorf J et al (2017) Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Thromb Haemost 116(07):191\u2013197","journal-title":"Thromb Haemost"},{"issue":"01","key":"2355_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1055\/s-0034-1374621","volume":"77","author":"JO Bock","year":"2014","unstructured":"Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W et al (2014) Ermittlung standardisierter Bewertungss\u00e4tze aus gesellschaftlicher Perspektive f\u00fcr die gesundheits\u00f6konomische Evaluation. Das Gesundheitswesen 77(01):53\u201361","journal-title":"Das Gesundheitswesen"},{"issue":"4","key":"2355_CR15","doi-asserted-by":"publisher","first-page":"2000663","DOI":"10.1183\/13993003.00663-2020","volume":"56","author":"L Hobohm","year":"2020","unstructured":"Hobohm L, Anu\u0161i\u0107 T, Konstantinides SV, Barco S (2020) Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolism (HoT-PE) trial. Eur Respir J 56(4):2000663","journal-title":"Eur Respir J"},{"key":"2355_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajem.2020.12.042","volume":"41","author":"JR Bledsoe","year":"2021","unstructured":"Bledsoe JR, Woller SC, Stevens SM, Aston V, Patten R, Allen T et al (2021) Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study. Am J Emerg Med 41:80\u201383","journal-title":"Am J Emerg Med"},{"key":"2355_CR17","first-page":"127","volume":"122","author":"SV Hendriks","year":"2021","unstructured":"Hendriks SV, Hout W, van Bemmel T, Bistervels IM, Eijsvogel M, Faber LM et al (2021) Home treatment compared to initial hospitalization in normotensive patients with acute pulmonary embolism in the netherlands: a cost analysis. Thromb Haemost 122:127\u2013133","journal-title":"Thromb Haemost"},{"issue":"2","key":"2355_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ehjqcco\/qcz035","volume":"6","author":"N Gustafsson","year":"2020","unstructured":"Gustafsson N, Poulsen PB, Stallknecht SE, Dybro L, Paaske JS (2020) Societal costs of venous thromboembolism and subsequent major bleeding events: a national register-based study. Eur Heart J Qual Care Clin Outcomes 6(2):130\u2013137","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2355_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad655.1984","author":"IT Farmakis","year":"2023","unstructured":"Farmakis IT, Valerio L, Barco S, Alsheimer E, Ewert R, Giannakoulas G et al (2023) Cardiopulmonary exercise testing in the follow-up after acute pulmonary embolism. Eur Respir J. https:\/\/doi.org\/10.1093\/eurheartj\/ehad655.1984","journal-title":"Eur Respir J"},{"issue":"5","key":"2355_CR20","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.chest.2016.11.030","volume":"151","author":"SR Kahn","year":"2017","unstructured":"Kahn SR, Hirsch AM, Akaberi A, Hernandez P, Anderson DR, Wells PS et al (2017) Functional and exercise limitations after a first episode of pulmonary embolism: results of the ELOPE prospective cohort study. Chest 151(5):1058\u20131068","journal-title":"Chest"},{"key":"2355_CR21","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/j.chest.2021.01.071","volume":"159","author":"L Valerio","year":"2021","unstructured":"Valerio L, Barco S, Jankowski M, Rosenkranz S, Lankeit M, Held M et al (2021) Quality of life three and twelve months after acute pulmonary embolism: analysis from a prospective multicenter cohort study. Chest 159:2428\u20132438","journal-title":"Chest"},{"key":"2355_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.thromres.2022.12.013","volume":"222","author":"S Fischer","year":"2023","unstructured":"Fischer S, Meisinger C, Linseisen J, Berghaus TM, Kirchberger I (2023) Depression and anxiety up to two years after acute pulmonary embolism: prevalence and predictors. Thromb Res 222:68\u201374","journal-title":"Thromb Res"},{"issue":"3","key":"2355_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/eurheartj\/ehab816","volume":"43","author":"FA Klok","year":"2022","unstructured":"Klok FA, Ageno W, Ay C, Back M, Barco S, Bertoletti L et al (2022) Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. Eur Heart J 43(3):183\u2013189","journal-title":"Eur Heart J"},{"key":"2355_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.thromres.2021.08.012","volume":"206","author":"G Boon","year":"2021","unstructured":"Boon G, Janssen SMJ, Barco S, Bogaard HJ, Ghanima W, Kroft LJM et al (2021) Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in post-PE syndrome. Thromb Res 206:66\u201375","journal-title":"Thromb Res"},{"issue":"6","key":"2355_CR25","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.3390\/jcm9061811","volume":"9","author":"S Nopp","year":"2020","unstructured":"Nopp S, Klok FA, Moik F, Petrovic M, Derka I, Ay C et al (2020) Outpatient pulmonary rehabilitation in patients with persisting symptoms after pulmonary embolism. J Clin Med 9(6):1811","journal-title":"J Clin Med"},{"key":"2355_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.thromres.2018.02.009","volume":"170","author":"SN Willich","year":"2018","unstructured":"Willich SN, Chuang LH, van Hout B, Gumbs P, Jimenez D, Kroep S et al (2018) Pulmonary embolism in Europe\u2014burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res 170:181\u2013191","journal-title":"Thromb Res"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02355-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02355-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02355-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:10:29Z","timestamp":1739977829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02355-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["2355"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02355-5","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SB received lecture\/consultant fees from Bayer HealthCare, Concept Medical, BTG Pharmaceuticals, INARI, Boston Scientific, and LeoPharma; institutional grants from Boston Scientific, Bentley, Bayer HealthCare, INARI, Medtronic, Concept Medical, Bard, and Sanofi; and economical support for travel\/congress costs from Daiichi Sankyo, BTG Pharmaceuticals, and Bayer HealthCare, outside the submitted work. SVK reports institutional grants and personal lecture\/advisory fees from Bayer AG, Daiichi Sankyo, and Boston Scientific; institutional grants from Inari Medical; and personal lecture\/advisory fees from MSD and Bristol Myers Squibb\/Pfizer. The remaining authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}